comparemela.com

Latest Breaking News On - Acadia pharmaceuticals inc - Page 8 : comparemela.com

Stephen Davis Sells 17,714 Shares of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Stock

Stephen Davis Sells 17,714 Shares of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesStephen davisStifel nicolausGroup plcEmpire life investments incAmeritas investment partners incAcadia pharmaceuticals incPharmaceuticals incPharmaceuticals price performancePharmaceuticals company profileSecurities exchange commissionPharmaceuticals dailyGet free reportExchange commissionLife investmentsGeneral group plc

1 secretly cheap ASX stock I m buying for the long run

1 secretly cheap ASX stock I m buying for the long run
fool.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com.au Daily Mail and Mail on Sunday newspapers.

Western australiaAcadia pharmaceuticals incNeuren pharmaceuticalsNeuren pharmaceuticals ltdCulper researchElvest fundPharmaceuticals ltd

ACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 1-Year Low on Analyst Downgrade

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) reached a new 52-week low during trading on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $29.00 to $25.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. ACADIA Pharmaceuticals traded as low as $17.56 and last traded […]

United statesStephen davisStifel nicolausPharmaceuticals dailyEmpire life investments incPharmaceuticals incAmeritas investment partners incPharmaceuticals company profilePharmaceuticals stock performanceSecurities exchange commissionGroup plcJpmorgan chase coAcadia pharmaceuticals incGet free reportExchange commissionLife investments

ACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 1-Year Low on Analyst Downgrade

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) reached a new 52-week low during trading on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $29.00 to $25.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. ACADIA Pharmaceuticals traded as low as $17.56 and last traded […]

United statesStifel nicolausStephen davisAcadia pharmaceuticals incJpmorgan chase coGroup plcSecurities exchange commissionPharmaceuticals company profileAmeritas investment partners incPharmaceuticals incEmpire life investments incPharmaceuticals stock performancePharmaceuticals dailyGet free reportExchange commissionLife investments

Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day

Acadia Pharmaceuticals Inc. today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time. The conference will be held virtually. A live.

Acadia pharmaceuticalsAcadia pharmaceuticals inc

vimarsana © 2020. All Rights Reserved.